Antibodies directed to the deletion mutants of epidermal...

Details Antibodies directed to the deletion mutants of epidermal... Antibodies directed to the deletion mutants of epidermal...

2004-06-25

2009-12-08

Huynh, Phuong (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S141100, C424S143100, C424S178100, C424S179100, C435S810000, C530S387100, C530S388100, C530S388150, C530S388220, C530S391100

Reexamination Certificate

active

07628986

ABSTRACT:
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 3896111 (1975-07-01), Kupchan et al.
patent: 4485045 (1984-11-01), Regen et al.
patent: 4544545 (1985-10-01), Ryan
patent: 4681581 (1987-07-01), Coates
patent: 4735210 (1988-04-01), Goldenberg
patent: 5101827 (1992-04-01), Goldenberg
patent: 5102990 (1992-04-01), Rhodes
patent: 5194594 (1993-03-01), Thompson et al.
patent: 5212290 (1993-05-01), Vogelstein et al.
patent: 5401020 (1995-03-01), Goldenberg
patent: 5576288 (1996-11-01), Lappi et al.
patent: 5627052 (1997-05-01), Vogelstein
patent: 5648471 (1997-07-01), Buttram
patent: 5697902 (1997-12-01), Goldenberg
patent: 5710010 (1998-01-01), Vogelstein
patent: 5814317 (1998-09-01), Vogelstein et al.
patent: 5939598 (1999-08-01), Kucherlapati
patent: 5981725 (1999-11-01), Vogelstein et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6127126 (2000-10-01), Vogelstein et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6224868 (2001-05-01), Wong et al.
patent: 6235883 (2001-05-01), Jakobovits et al.
patent: 6342219 (2002-01-01), Thorpe
patent: 6441163 (2002-08-01), Chari et al.
patent: 6455498 (2002-09-01), Vogelstein et al.
patent: 6673986 (2004-01-01), Kucherlapati et al.
patent: 7084257 (2006-08-01), Deshpande et al.
patent: 639726 (1991-04-01), None
patent: 2066428 (1990-08-01), None
patent: 69025946 (1996-04-01), None
patent: 36676 (1981-09-01), None
patent: 58481 (1982-08-01), None
patent: 88046 (1983-09-01), None
patent: 102324 (1984-03-01), None
patent: 142641 (1985-05-01), None
patent: 143949 (1985-06-01), None
patent: 491007 (1992-06-01), None
patent: 0 463 151 (1996-06-01), None
patent: 607934 (1985-01-01), None
patent: 3 068 180 (1991-03-01), None
patent: 3 068 506 (1991-03-01), None
patent: 3 068 507 (1991-03-01), None
patent: 2975679 (1999-11-01), None
patent: WO 91/03489 (1991-03-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 96/16988 (1996-06-01), None
patent: WO 9616988 (1996-06-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 00/76310 (2000-12-01), None
patent: WO 01/00244 (2001-01-01), None
patent: WO 01/62931 (2001-08-01), None
patent: WO 03/047336 (2003-06-01), None
Doronnina et al, Nature Biotechnology 21(7): 778-784,941, Jul. 2003.
Mohammad et al, Clin Cancer Res 4(5): 1337-43, May 1998.
Liu et al, Proc. Natl. Acad. Sci. U.S.A 93: 8618-8623, Aug. 1996.
Toki et al, Abstracts of Papers of the American Chemical Society 223(2): A113, Apr. 7-11, 2002.
Kuby et al, Immunology, Second edition, pp. 86-96, 1994.
Kobrin et al, J Immunology 146:2017-2020, 1991.
Barrios et al, J Molecular Recognition 17: 332-338, 2004.
Yang et al, Crit. Rev Oncol Hematol 38: 17-23, 2001.
U.S. Appl. No. 07/404,226, filed Sep. 8, 1989, Vogelstein.
U.S. Appl. No. 07/531,410, filed Jun. 1, 1990, Vogelstein.
Mendelsohn, Cancer Cells 7:359 (1989).
Mendelsohn, “Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents”, J Steroid Biochem Mol Biol, Dec 20, 1990: 37 (6): 889-92.
Mendelsohn, The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies, Semin Cancer Biol, Oct. 1990; 1(5):339-44.
Schmidt et al., Expression of an Oncogenic Mutant EGF Receptor Markedly Increases The Sensitivity of Cells to an EGF-Receptor-Specific Antibody-Toxin,Int. J. Cancer, 75, 878-884 (Mar. 16, 1998).
Janeway et al. “The Structure of typical Antibody Molecule,”Immunobiology, 1994, 3:1-3:3.
Green et al. “Generation and characterization of fully human EGFRvIII antibodies suitable for immunoconjugates” American Association for Cancer Research Annual Meeting, Mar. 2004.
Jungbluth et al. “A monoclonal antibody recognizing human cancers with amplification / overexpression of the human epidermal growth factor receptor” Proc Nat Acad Sci 100(2): 639-644, Jan. 2003.
Sampson et al. “Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors” Proc Nat Acad Sci 97(13): 7503-7508, Jun. 2000.
Jorissen et al. “Epidermal growth factor receptor: mechanisms of activation and signaling” Experimental Cell Research 284 (2003) 31-53.
Luwor et al. Monoclonal Antibody 806 Inhibits the Growth of Tumor Xenografts Expressing Either the de2-7 or Amplified Epidermal Growth Factor Receptor (EGFR) but not Wild-Type EGFR.
Office Action dated Nov. 16, 2007, received in U.S. Appl. No. 10/877,774.
Johns et al. “Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene” Int J Cancer 98: 398-408 (2002).
U.S. Appl. No. 07/466,008, filed Jan. 12, 1990.
U.S. Appl. No. 07/610,515, Nov. 8, 1990.
U.S. Appl. No. 07/919,297, filed Jul. 30, 1992.
U.S. Appl. No. 08/112,848, filed Aug. 27, 1993.
U.S. Appl. No. 08/234,145, filed Apr. 28, 1994.
U.S. Appl. No. 08/376,279, filed Jan. 20, 1995.
U.S. Appl. No. 08/430,938, filed Apr. 27, 1995.
U.S. Appl. No. 08/462,837, filed Jun. 5, 1995.
U.S. Appl. No. 08/463,191, filed Jun. 5, 1995.
U.S. Appl. No. 08/464, 584, filed Jun. 5, 1995.
U.S. Appl. No. 08/486,853, filed Jun. 5, 1995.
U.S. Appl. No. 08/486,859, filed Jun. 5, 1995.
U.S. Appl. No. 08/759,620, filed Dec. 3, 1996.
Babcook et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A.93(15):7843-8 (1996).
Batra et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occuring human mutant EGFRvIII gene. Cell Growth Differ. 8(10):125-9 (1995).
Bigner et al., (1988) J. Neuropathol. Exp. Neurol., 47:191-205.
Bumol et al, In Antibody Mediated Delivery Systems 55-79 (J. Rodwell, ed. 1988).
Chothia, et al. (Nature. Dec. 21-28, 1989;342(6252):877-83).
Deo et al. Immunology Today (1997) 18:127.
Diener et al, In Antobody Mediated Delivery Systems 1-23 (J. Rodwell, ed. 1988).
Dillman et al. Superiority of an Acid-labile Daunorubicin-Monoclonal antibody Immunoconjugate compared to free drug. Cancer Res. (1988) 48:6097-6102.
Dillman et al. Preclinical trials with conbinations and conjugates of T101 monoclonal antibody and doxorubicin. Cancer Res. (1986) 46:4886-4891.
Doronina et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology. (2003) 21: 778-784.
Downward et al. Close Similarity of Epidermal Growth Factor Receptor and v-erbB Oncogene Protein Sequence. Nature (1984) 307:521-527.
Dubowchik et al. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel: (Taxol), mitomycin C and doxorubicin Bloorg Med Chem Lett. (1998) 8(23):3347-52.
Endo et al. Cancer Res. (1980) 47:1076-1080.
Francisco et al. cAC10-vcMMAE, and anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. Aug. 15, 2003 [Epub ahead of print]. Epub Apr. 24, 2003.
Fung et al., (1984) Activation of the Cellular Oncogene c-erb B by LTR Insertion: Molecular Basic for Induction of Erythroblastosis by Avian Leukosis Virus. Cell 33:357-368.
Gammett et al., (1986). Differences in Sequences Encoding the Carboxy-Terminal Domain of the Epidermal Growth Factor Receptor Correlate with Differences in the Disease Potential of Viral erbB Genes. Proc. Natl. Acad. Sci. USA 83:6053-6057).
Garcia de Palazzo,

Affiliated with

Also associated with

Rating

Antibodies directed to the deletion mutants of epidermal... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies directed to the deletion mutants of epidermal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies directed to the deletion mutants of epidermal... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4147557